Safety of intravenous ferric carboxymaltose versus oral iron in patients with nondialysis-dependent CKD: An analysis of the 1-year FIND-CKD trial

Nephrology Dialysis Transplantation

Volumn 32, Issue 9, 2017, Pages 1530-1539

  Roger, Simon D ^a   Gaillard, Carlo A ^b   Bock, Andreas H ^c   Carrera, Fernando ^c   Eckardt, Kai Uwe ^d   Van Wyck, David B ^e   Cronin, Maureen ^f   Meier, Yvonne ^f   Larroque, Sylvain ^f   MacDougall, Iain C ^g  

^a Renal Research   (Australia)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c Department of Nephrology ^*  (Portugal)

^d UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^e DaVita HealthCare Partners   (United States)

^f Vifor (International) Inc   (Switzerland)

^g KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

Anemia; cardiovascular disease; oxidative stress

Indexed keywords

FERRIC CARBOXYMALTOSE; FERRITIN; FERROUS SULFATE; IRON; FERRIC ION; MALTOSE;

AGED; ARTICLE; CHRONIC KIDNEY FAILURE; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FERRITIN BLOOD LEVEL; FOLLOW UP; GASTROINTESTINAL DISEASE; GLOMERULUS FILTRATION RATE; HEART DISEASE; HEMATOLOGIC DISEASE; HUMAN; INCIDENCE; INFECTION; INJURY; IRON DEFICIENCY ANEMIA; KIDNEY DISEASE; LYMPHATIC SYSTEM DISEASE; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; NEOPLASM; NEUROLOGIC DISEASE; NUTRITIONAL DISORDER; PERIPHERAL EDEMA; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; SKIN DISEASE; VASCULAR DISEASE; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; COMPLICATION; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; TIME FACTOR;

ADMINISTRATION, INTRAVENOUS; ADMINISTRATION, ORAL; AGED; ANEMIA, IRON-DEFICIENCY; FEMALE; FERRIC COMPOUNDS; GLOMERULAR FILTRATION RATE; HUMANS; IRON; MALE; MALTOSE; PROSPECTIVE STUDIES; RENAL INSUFFICIENCY, CHRONIC; TIME FACTORS;

EID: 85018014099     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfw264     Document Type: Article

References (15)

1. Fishbane S, Pollack S, Feldman HI et al. Iron indices in chronic kidney disease in the National Health and Nutritional Examination Survey 1988-2004. Clin J Am Soc Nephrol 2009; 4: 57-61
2. Camaschella C, Strati P. Recent advances in ironmetabolismand related disorders. Intern EmergMed 2010; 5: 393-400
3. Kidney Disease Improving Global Outcomes (KDIGO). Clinical practice guideline for anemia in chronic kidney disease. Kidney Int Suppl 2012; 4: 279-335
4. Macdougall IC. Intravenous iron therapy in non-dialysis CKD patients. Nephrol Dial Transplant 2014; 29: 717-720
5. Geisser P, Burckhardt S. The pharmacokinetics and pharmacodynamics of iron preparations. Pharmaceutics 2011; 3: 12-33
6. Vaziri ND. Understanding iron: promoting its safe use in patients with chronic kidney failure treated by hemodialysis. Am J Kidney Dis 2013; 61: 992-1000
7. Parkkinen J, von Bonsdorff L, Peltonen S et al. Catalytically active iron and bacterial growth in serum of haemodialysis patients after i.v. iron-saccharate administration. Nephrol Dial Transplant 2000; 15: 1827-1834
8. Rozen-Zvi B, Gafter-Gvili A, Paul M et al. Intravenous versus oral iron supplementation for the treatment of anemia in CKD: systematic review and meta-analysis. Am J Kidney Dis 2008; 52: 897-906
9. Macdougall IC, Bircher AJ, Eckardt KU et al. Iron management in chronic kidney disease: conclusions from a 'Kidney Disease: Improving Global Outcomes' (KDIGO) controversies conference. Kidney Int 2016; 89: 23-39
10. Macdougall IC, Bock AH, Carrera F et al. FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in psatient with chronic kidney disease and iron deficiency anaemia. Nephrol Dial Transplant 2014; 29: 2075-2084
11. Levey AS, Bosch JP, Lewis JB et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann InternMed 1999; 130: 461-470
12. Agarwal R, Kusek JW, Pappas MK. A randomized trial of intravenous and oral iron in chronic kidney disease. Kidney Int 2015; 88: 905-914
13. QunibiWY, Martinez C, Smith M et al. A randomized controlled trial comparing intravenous ferric carboxymaltose with oral iron for treatment of iron deficiency anaemia of non-dialysis-dependent chronic kidney disease patients. Nephrol Dial Transplant 2011; 26: 1599-1607
14. Kalra PA, Bhandari S, Saxena S et al. A randomized trial of iron isomaltoside 1000 versus oral iron in non-dialysis-dependent chronic kidney diseasepatients with anaemia. Nephrol Dial Translant 2015; 30: 1577-1589
15. Moore RA, Gaskell H, Rose P et al. Meta-analysis of efficacy and safety of intravenous ferric carboxymaltose (Ferinject) from clinical trial reports and published trial data. BMC Blood Disorders 2011; 11: 4